Julia Fonte
Psychiatric/Mental Health, Adult · Carmel, INNPI 1366565004
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.1% of the total across 797 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations.
Across 797 payments — averaging $25.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Alkermes, Inc.$2K
- Axsome Therapeutics, Inc.$1K
- Biohaven Pharmaceuticals, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $8K from 27 others
What the payments were for
- Consulting fees$8004%
- Food & beverage$19,40594%
- Education$4072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 211 | $4,786 |
| Alkermes, Inc. | 60 | $2,159 |
| Axsome Therapeutics, Inc. | 56 | $1,422 |
| Biohaven Pharmaceuticals, Inc. | 7 | $1,337 |
| Otsuka America Pharmaceutical, Inc. | 53 | $1,287 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $1,249 |
| Teva Pharmaceuticals USA, Inc. | 31 | $1,233 |
| Vanda Pharmaceuticals Inc. | 21 | $853 |
| Neurocrine Biosciences, Inc. | 24 | $687 |
| Supernus Pharmaceuticals, Inc. | 61 | $681 |
| Neos Therapeutics, LP | 48 | $663 |
| Johnson & Johnson | 27 | $646 |
| Tris Pharma Inc | 14 | $560 |
| Corium, LLC | 15 | $453 |
| Novo Nordisk | 3 | $368 |
| Sunovion Pharmaceuticals Inc. | 42 | $348 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $267 |
| Noven Therapeutics, LLC | 15 | $237 |
| E.r. Squibb & Sons, L.L.C. | 3 | $223 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $223 |
| Eisai Inc. | 7 | $146 |
| Lundbeck LLC | 8 | $146 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $112 |
| Ironshore Pharmaceuticals Inc. | 4 | $88 |
| Evofem Biosciences, Inc. | 5 | $80 |
| Almatica Pharma LLC | 5 | $79 |
| Adlon Therapeutics L.p. | 4 | $67 |
| Lilly USA, LLC | 4 | $61 |
| Amgen | 2 | $45 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 2 | $32 |
| Biogen | 1 | $26 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,994
- ARISTADA$1,395
- NURTEC ODT$1,336
- VRAYLAR$958
- UBRELVY$486
- CAPLYTA$479
- Auvelity$443
- Wegovy$368
- REXULTI$354
- Fanapt$342
- Dyanavel XR$248
- Quillichew ER$248
- Quillivant$248
- QULIPTA$244
- QELBREE$237
- UZEDY$235
- ARISTADA INITIO$224
- AUSTEDO$127
- SPRAVATO$123
- Austedo XR$118
How this compares
Too few psychiatric/mental health, adult providers in Indianato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 23 | $181,169 |
| SpravatoEsketamine Hcl | 23 | $29,214 |
| VraylarCariprazine Hcl | 11 | $15,281 |
| TrintellixVortioxetine Hydrobromide | 15 | $12,739 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 39 | $2,527 |
| Aripiprazole | 20 | $1,977 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 31 | $1,193 |
| Duloxetine Hcl | 22 | $971 |
| Bupropion XlBupropion Hcl | 36 | $960 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 16 | $792 |
| Lurasidone Hcl | 15 | $790 |
| Clonazepam | 74 | $617 |
| Alprazolam | 115 | $458 |
| Zolpidem Tartrate | 25 | $323 |
| Lorazepam | 40 | $294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $687 | $181,16923 claims |
| Johnson & JohnsonSpravato | $646 | $29,21423 claims |
| AbbVieVraylar | $4,786 | $15,28111 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $267 | $12,73915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, adult providers in Indianaon file to place this against a meaningful peer group, so we don't.
Other psychiatric/mental health, adult in Carmel
- Deborah BykowskiCarmel$3K
- Cynthia WilsonCarmel$2K
- Lyndsay HillIndianapolis$6K
- Thelma Young-BoldenBloomington$6K
- Noreen NowakIndianapolis$2K
- Mary HessionIndianapolis$1K
- Ashlynn DavisLafayette$1K
- Jane NewkirkIndianapolis$1K
- Leah KnightIndianapolis$1K
- Valerie MarkleyTerre Haute$732
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.